FDA Expands Trulicity Label to Include Cardiovascular Risk Reduction in Type 2 Diabetes

Eli Lilly has secured a significant expansion of its Trulicity (dulaglutide) label, with the FDA approving the GLP-1 receptor agonist for reducing major adverse cardiovascular events (MACE) in adults with type 2 diabetes. The approval covers both patients with established cardiovascular disease and those with multiple cardiovascular risk factors.

The expanded indication, supported by data from the REWIND trial, positions Trulicity as the only diabetes medication approved in the United States for both primary and secondary prevention of MACE in the type 2 diabetes population.

REWIND Trial Results

The REWIND cardiovascular outcomes trial demonstrated meaningful clinical benefits, with Trulicity reducing the five-year MACE rate to 2.4% compared to 2.7% in the placebo group. The study evaluated cardiovascular outcomes in type 2 diabetes patients, though researchers noted no significant difference in overall mortality rates between treatment groups.

Competitive Landscape

This label expansion comes at a crucial time as Trulicity faces increasing competition in the GLP-1 agonist market, particularly from Novo Nordisk's Ozempic (semaglutide). While Trulicity maintains its market leadership with $4.13 billion in sales for the previous year (representing 29% growth), Ozempic has shown remarkable growth, reaching $1.6 billion in sales with a 142% increase.

Comparative Cardiovascular Data

Ozempic, which received its own MACE risk reduction label earlier this year, demonstrated positive results in the SUSTAIN 6 trial. The study showed a reduction in cardiovascular events to 6.6% compared to 8.9% with placebo in type 2 diabetics, though it achieved non-inferiority rather than superiority for cardiovascular death rates.

Market Implications

The expanded label strengthens Trulicity's position in the increasingly competitive GLP-1 receptor agonist market. The approval is particularly significant as it covers both primary and secondary prevention, potentially differentiating it from other options in the class.

The European Medicines Agency is currently reviewing the REWIND trial data, with a decision pending on a similar label expansion in the EU market.